Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome

Figures & data

Table 1 Mean aqueous humor levels of matrix metalloproteinase-2 (MMP-2), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and transforming growth factor beta 1 (TGF-β1) in patients

Aqueous	n	TGF-β1 (pg/mL)	MMP-2 (ng/mL)	TIMP-2 (ng/mL)
Cataract control	10	820.6±323.0	25.3±1.4	35.9±15.2
PEX syndrome	12	648.0±282.0	25.1±1.5	30.6±8.1
PEX glaucoma	10	733.1±280.0	25.4±2.6	41.5±16.5
PEX total	22	686.8±278.3	25.3±2.0	35.5±13.5

Note: Data are expressed as mean ± standard deviation.

Abbreviation: PEX, pseudoexfoliation.

Table 2 Mean serum levels of matrix metalloproteinase-2 (MMP-2), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and transforming growth factor beta 1 (TGF-β1) in patients

Serum	n	TGF-β1 (pg/mL)	MMP-2 (ng/mL)	TIMP-2 (ng/mL)
Cataract control	10	31,200±12,081	186.2±60.6	38.0±14.5
PEX syndrome	12	36,487±7,132	204.5±59.9	46.9±14.4
PEX glaucoma	10	36,381±7,597	180.5±46.5	51.2±18.9
PEX total	22	36,439±7,169	193.6±50.4	48.9±16.3

Note: Data are expressed as mean ± standard deviation.

Abbreviation: PEX, pseudoexfoliation.

Table 3 Mean concentrations of matrix metalloproteinase-2 (MMP-2), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and transforming growth factor beta 1 (TGF-β1) in the aqueous humor of patients with pseudoexfoliation (PEX) glaucoma

Study	TGF-β1		MMP-2		TIMP-2
	n	pg/mL	n	ng/mL	n	ng/mL
Konstas et al^Citation12
Timolol group	30	13.40±1.50	30	81.50±7.20	20	101.28±7.29
Latanoprost group	30	3.10±0.65	30	31.75±3.80	20	73.80±6.81
Määttä et al^Citation9			16	77.40±33.80	16	98.20±35.80
Takai et al^Citation11	21	67.70±58.70
Schlötzer-Schrehardt^Citation13			30	107.50±60.20	15	114.50±48.70
Djordjević-Jocić et al^Citation10	36	147.00±76.54	36	29.00±16.80	36	43.50±19.70
Kara et al	10	733.10±280.0	10	25.40±2.60	10	41.50±16.50

Note: Data are expressed as mean ± standard deviation.

KonstasAGKoliakosGGKarabatsasCHLatanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humour of patients with exfoliative glaucomaExp Eye Res200682231932216115621

 PubMed Web of Science ®Google Scholar

MäättäMTervahartialaTHarjuMAiraksinenJAutio-HarmainenHSorsaTMatrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucomaJ Glaucoma2005141646915650607

 PubMed Web of Science ®Google Scholar

TakaiYTanitoMOhiraAMultiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataractInvest Ophthalmol Vis Sci201253124124722159018

 PubMed Web of Science ®Google Scholar

Schlötzer-SchrehardtU[Oxidative stress and pseudoexfoliation glaucoma]Klin Monbl Augenheilkd20102272108113 German20155654

 PubMed Web of Science ®Google Scholar

Djordjević-JocićJZlatanovićGVeselinovićDTransforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma/syndromeVojnosanit Pregl201269323123622624408

 PubMed Web of Science ®Google Scholar